On October 25, 2021, Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering were approximately $174.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Ventyx. All shares in the offering were offered by Ventyx and began trading on the Nasdaq Global Select Market on October 21, 2021, under the ticker symbol “VTYX.”

Wilson Sonsini Goodrich & Rosati advised Ventyx on the offering. The team includes corporate attorneys Marty Waters, Rob Wernli, and Carson Williams and patent attorneys Mike Hostetler, Ingo Hardt, and Jim Malecha.

For more information, please see Ventyx’s press release.